The "dementia profile" is used to reduce false positives on the Word Memory Test (WMT). Provided that this profile reflects genuine memory impairment, corresponding cognitive deficits should be found in neuropsychological testing. We examined whether a WMT dementia profile is a significant indicator of cognitive impairment and/or decline. In addition, we evaluated the classification accuracy for the clinical diagnosis of dementia. Elderly patients (n = 167) with cognitive complaints were given an extensive neuropsychological test battery, including the WMT. This was repeated 2 years later. The results demonstrate that patients with the dementia profile have a higher chance of showing real cognitive impairment at baseline, and even more so 2 years later. They showed a faster cognitive decline than patients who passed the WMT effort subtasks. Sensitivity of the profile was a moderate 60%. However, the positive predictive value was high, viz. 81% at baseline and 93% at follow-up.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/arclin/act026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case Series of Right-Hemisphere Nonfluent Variant of Primary Progressive Aphasia.
J Clin Neurol
January 2025
Brain and Mind Centre, The University of Sydney, Camperdown, NSW, Australia.
Background And Purpose: Nonfluent variant primary progressive aphasia (nfvPPA) is a neurodegenerative disorder characterized by the progressive deterioration of language functions that typically appears with atrophy predominating in the left peri-insular region (left-nfvPPA) on imaging. While both left-dominant and right-dominant presentations have been reported in semantic variant primary progressive aphasia, the other language presentation of frontotemporal dementia, no case series of nfvPPA with predominantly right-sided atrophy of the peri-insular region (right-nfvPPA) have been reported previously. This study explored whether such entities exist and what their clinical features might be.
View Article and Find Full Text PDFUncovering the epigenetic regulatory clues of PRRT1 in Alzheimer's disease: a strategy integrating multi-omics analysis with explainable machine learning.
Alzheimers Res Ther
January 2025
Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, 818 Fenghua Road, Jiangbei District, Ningbo, China.
Background: Alzheimer's disease (AD) is a complex neurodegenerative disorder with a largely unexplored epigenetic landscape.
Objective: This study employs an innovative approach that integrates multi-omics analysis and explainable machine learning to explore the epigenetic regulatory mechanisms underlying the epigenetic signature of PRRT1 implicated in AD.
Methods: Through comprehensive DNA methylation and transcriptomic profiling, we identified distinct epigenetic signatures associated with gene PRRT1 expression in AD patient samples compared to healthy controls.
Comprehensive Transcriptomic Analysis Reveals Cell-Type-Specific Roles of Human Odorant Receptors in Glioblastoma and the Tumor Microenvironment.
Int J Mol Sci
December 2024
Department of New Biology, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Republic of Korea.
Odorant receptors (ORs), which constitute approximately 50% of all human G protein-coupled receptors, are increasingly recognized for their diverse roles beyond odor perception, including functions in various pathological conditions like brain diseases and cancers. However, the roles of ORs in glioblastoma (GBM), the most aggressive primary brain tumor with a median survival of only 15 months, remain largely unexplored. Here, we performed an integrated transcriptomic analysis combining The Cancer Genome Atlas RNA-seq and single-cell RNA sequencing data from GBM patients to uncover cell-type-specific roles of ORs within the tumor and its microenvironment.
View Article and Find Full Text PDFGalantamine-Memantine Combination in the Treatment of Parkinson's Disease Dementia.
Brain Sci
November 2024
Department of Public Safety and Correctional Services, Baltimore, MD 21215, USA.
Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects over 1% of population over age 60. It is defined by motor and nonmotor symptoms including a spectrum of cognitive impairments known as Parkinson's disease dementia (PDD). Currently, the only US Food and Drug Administration-approved treatment for PDD is rivastigmine, which inhibits acetylcholinesterase and butyrylcholinesterase increasing the level of acetylcholine in the brain.
View Article and Find Full Text PDFIdentifying Hub Genes and miRNAs Associated with Alzheimer's Disease: A Bioinformatics Pathway to Novel Therapeutic Strategies.
Biomolecules
December 2024
Department of Anatomy, Embryology and Animal Genetics, University of Zaragoza, 50013 Zaragoza, Spain.
Alzheimer's disease (AD) is a neurodegenerative disorder that mainly affects the elderly population. It is characterized by cognitive impairment and dementia due to abnormal levels of amyloid beta peptide (Aβ) and axonal Tau protein in the brain. However, the complex underlying mechanisms affecting this disease are not yet known, and there is a lack of standardized biomarkers and therapeutic targets.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!